Maridebart represents a highly specialized humanized monoclonal antibody specifically engineered to target the human growth differentiation factor 15 with exceptional binding affinity and selectivity, effectively facilitating the measurable neutralization of ligand-mediated signaling within the GFRAL receptor pathway to evaluate its functional role in systemic metabolic regulation and the prevention of cancer-associated cachexia during strictly monitored laboratory observation periods and functional appetite regulation assays to ensure high experimental sensitivity and accuracy.